All In Biotech

Drug Trial Radar · NCT02183220

Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.

Last checked: Nov 19, 2026Latest source record: Jul 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 417 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

417

Actual

Start

Oct 1998

Primary completion

Jul 1999

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.

Conditions

  • Migraine Disorders

Interventions

  • MetamizolDrug

  • Acetylsalicylic acid (ASA)Drug

  • Metamizol placeboDrug

  • ASA placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.